Comparison
Bromantane vs Metformin
Side-by-side of Bromantane and Metformin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
Metformin
Metformin for longevity: biguanide mechanism of action, TAME trial status, anti-aging dosage, weight loss data, life extension evidence in non-diabetics.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
Metformin
- •Reduces HbA1c by ~1.0 to 1.5 percentage points in type 2 diabetes; first-line agent in major guidelines
- •DPP trial: 31% reduction in T2DM incidence in adults with prediabetes over 2.8 years
- •Suppresses hepatic gluconeogenesis via AMPK activation and complex I inhibition
- •Long-term use depletes B12; annual monitoring recommended after year 2
- •Lifespan extension in non-diabetic humans is not established; TAME trial pending
- •MASTERS trial reported blunted resistance-training hypertrophy in older adults
Side-by-side
| Attribute | Bromantane | Metformin |
|---|---|---|
| Category | nootropic | pharmaceutical |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | Glucophage, Fortamet, Glumetza, dimethylbiguanide |
| Half-life (hr) ↗ | 11 | 6 |
| Typical dose (mg) ↗ | 75 | 1500 |
| Dosing frequency | daily, morning | 1 to 3 times daily with meals; XR once daily |
| Routes | oral | oral |
| Onset (hr) | 3 | 1 |
| Peak (hr) | 168 | 2.5 |
| Molecular weight | 280.21 | 129.16 |
| Molecular formula | C16H20BrN | C4H11N5 |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Suppresses hepatic gluconeogenesis primarily via AMPK activation and complex I inhibition; modestly improves peripheral insulin sensitivity and shifts gut microbiome composition. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | Prescription only (FDA approved for type 2 diabetes 1994) |
| WADA status | banned | allowed |
| DEA / Rx | Not scheduled in the US | Rx only (not a controlled substance) |
| Pregnancy | Not recommended | Category B; used in gestational diabetes and PCOS per current guidance |
| CAS | 87913-26-6 | 657-24-9 |
| PubChem CID | 9576456 | 4091 |
| Wikidata | Q4093816 | Q19484 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
Metformin
Common side effects
- nausea
- diarrhea
- abdominal discomfort
- metallic taste
- decreased appetite
- B12 depletion (long-term)
Contraindications
- eGFR below 30 mL/min/1.73m2
- acute or chronic metabolic acidosis
- severe hepatic impairment
- acute heart failure
- iodinated contrast within 48 hours
Interactions
- iodinated contrast media: renal injury risk; hold 48 hours peri-imaging(major)
- alcohol (heavy use): elevated lactic acidosis risk(major)
- cimetidine: raises metformin plasma levels via OCT2 inhibition(moderate)
- insulin and sulfonylureas: additive hypoglycemia risk in combination(moderate)
- dolutegravir: raises metformin exposure via OCT2(moderate)
Which Should You Take?
Metformin comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. Bromantane is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Bromantane.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is metabolic health and glucose control, pick Metformin.
- → If your priority is healthspan extension, pick Metformin.
Default choice: Metformin. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Bromantane only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and Metformin?
Bromantane and Metformin differ in category (nootropic vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or Metformin?
Bromantane half-life is 11 hours; Metformin half-life is 6 hours.
Can you stack Bromantane with Metformin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper